6/30/26
Therapeutic Dosing Strategies and Titration Regimens for the CM4 Protocol
— Raul Pint, creator of CM4
The clinical efficacy and safety of the CM4 protocol depend entirely on exact, biomarker-driven dosing. Because these compounds alter renal hemodynamics, fluid balance, and electrolyte handling, clinician-guided titration is required.
The following sections outline the established pharmacological dosing ranges for each component of the CM4 matrix.
Morning Phase: Glucosuric and Volume-Offloading Core
Empagliflozin:
Standard Dose: 10 mg or 25 mg orally, administered once daily in the morning.
Clinical Rationale: The 10 mg starting dose is typically sufficient to achieve the desired ~60–80g daily urinary glucose excretion, effectively dropping the insulin-to-glucagon ratio. Titration to 25 mg may be considered in patients with an eGFR > 60 mL/min/1.73m² who exhibit a plateau in viscerolypolytic activity, provided that strict genitourinary hygiene is maintained.
Low-Dose Thiazide-Like Diuretic (e.g., Indapamide or Hydrochlorothiazide):
Standard Dose: Indapamide (1.25 mg to 2.5 mg) or Hydrochlorothiazide (12.5 mg to 25 mg) orally, once daily in the morning.
Clinical Rationale: Using the lowest effective dose minimizes the risk of severe reflex RAAS activation while still providing synergistic proximal and distal convoluted tubule natriuresis when combined with empagliflozin.
Midday Phase: Endothelial and Perfusion Support
L-Arginine:
Standard Dose: 3,000 mg to 6,000 mg daily, administered orally in divided doses (e.g., 1,500 mg to 3,000 mg taken at midday and early afternoon).
Clinical Rationale: Due to the short plasma half-life of oral L-arginine (approximately 1.5 to 2 hours) and extensive first-pass hepatic metabolism, higher divided doses are required to maintain a steady pool of substrate for endothelial nitric oxide synthase (eNOS). This specific timing counters the peak volume-depleting effects of the morning medications, protecting the glomerular filtration rate.
Evening Phase: Ion Replacement and Bicarbonate Buffering
Potassium Citrate:
Standard Dose: 20 mEq to 40 mEq (approximately 2.16 g to 4.32 g) orally, administered once daily in the evening with food or a bedtime snack.
Clinical Rationale: The exact dose must be adjusted based on the patient's serum potassium levels and the intensity of the daytime diuretic regimen. The citrate fraction provides sustained systemic alkalization during the nocturnal fasting window. This buffers the steady accumulation of acidic ketone bodies, successfully preventing latent metabolic acidosis and protecting the myocardium from hypokalemia-induced arrhythmias during sleep.
Clinical Titration and Stop-Loss Criteria
The protocol should be initiated using a stepped approach. Typically, clinicians introduce the morning empagliflozin and evening potassium citrate during Week 1 to establish the glucosuric baseline. The low-dose thiazide and midday L-arginine are then introduced in Week 2, provided the patient's blood pressure and renal markers remain stable.
Therapy must be paused or the dosages down-titrated if serum creatinine increases by more than thirty percent above baseline, if eGFR drops below forty-five milliliters per minute, or if serum potassium falls below 3.5 mEq/L despite evening citrate supplementation.
